The Centers for Disease Control and Prevention (CDC) defines long COVID as health problems lasting four or more weeks after first getting infected with the novel coronavirus, impacting as many as one out of every four patients who are diagnosed with COVID-19. The aftermath of symptoms for self-described “long haulers” is unfortunately all too real: … Continued
Since the emergency use authorization of the first COVID-19 vaccine in December 2020, health experts have underscored that in order to combat the pandemic, vaccines must be widely available, accessible and reach people worldwide. To help make this a reality, the biopharmaceutical industry, governments and other stakeholders have been working tirelessly to scale up manufacturing … Continued
This year, the biopharmaceutical research industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. A key piece of that has been the impact the pandemic has had on mental health. PhRMA CEO Steve Ubl recently had the opportunity to … Continued
This year, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. A key piece of that has been the impact the pandemic has had on mental health. I had the opportunity to connect with Barry Greene, CEO of … Continued
After the mid-March shutdown, the month of May began with me working diligently, going from zoom to zoom and managing virtual school for my son. Above all, I was focused on keeping my son and myself safe from contracting COVID-19 and helping family, friends and colleagues through the sicknesses and loss of loved ones due … Continued
On May 19, Axios hosted an event discussing the unprecedented development of COVID-19 vaccines and the road ahead. Speakers included NIAID Director Dr. Anthony Fauci, Pfizer Chairman & CEO Dr. Albert Bourla and PhRMA President & CEO Stephen J. Ubl.
After more than 200 clinical trials and nearly 300 partnerships and collaborations among manufacturers worldwide, production has increased, in just a few months from zero to 2.2 billion COVID-19 vaccine doses by the end of May with an astounding estimate of 11 billion doses by the end of 2021 (Airfinity data here). This will be … Continued
Like many others around the world, America’s biopharmaceutical companies stand with those affected by the coronavirus. And while biopharmaceutical companies are working around the clock to meet the demands of COVID-19 by developing and delivering therapeutics and vaccines, we recognize that the coronavirus crisis in India requires urgent attention and collaborative solutions from stakeholders globally.
The COVID-19 pandemic has left no person unaffected, but Black Americans have been disproportionately impacted. Black adults are nearly four times more likely to be hospitalized from the virus and nearly three times more likely to die from the virus than their white counterparts. At the same time, recent polls highlight COVID-19 vaccine hesitancy within … Continued
PhRMA CEO Steve Ubl recently connected with Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. (USBC), which represents 310,000 Black-owned businesses nationwide, about how to improve vaccine confidence in communities of color.